AbbVie Inc. $ABBV Holdings Lowered by Boston Research & Management Inc.

Boston Research & Management Inc. decreased its stake in AbbVie Inc. (NYSE:ABBV) by 4.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 48,688 shares of the company’s stock after selling 2,450 shares during the quarter. AbbVie makes up approximately 2.6% of Boston Research & Management Inc.’s investment portfolio, making the stock its 6th largest position. Boston Research & Management Inc.’s holdings in AbbVie were worth $11,124,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of ABBV. Chelsea Counsel Co. purchased a new stake in shares of AbbVie in the third quarter worth about $26,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie in the fourth quarter worth about $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie in the third quarter worth about $31,000. Legacy Wealth Managment LLC ID boosted its stake in shares of AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after buying an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC boosted its stake in shares of AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after buying an additional 85 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on ABBV. William Blair reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Morgan Stanley raised their price objective on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective on the stock in a report on Thursday, April 30th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Monday. Finally, Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie Price Performance

NYSE ABBV opened at $225.16 on Thursday. The company has a market cap of $397.82 billion, a PE ratio of 110.92, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. The stock’s 50 day simple moving average is $210.64 and its 200-day simple moving average is $219.09. AbbVie Inc. has a 1-year low of $181.73 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.46 earnings per share. On average, equities research analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s migraine drug was cleared for use in migraine attacks on the NHS, a sign of broader adoption potential that could support future sales growth. AbbVie’s migraine drug cleared for migraine attacks on NHS
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, highlighted new consumer research in its aesthetics business, reinforcing ongoing brand visibility and interest in its aesthetics portfolio. Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’
• Neutral Sentiment: AbbVie presented at Goldman Sachs’ healthcare conference, which typically provides investors with updates on strategy and pipeline but did not include a major new catalyst in the headline. AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: AbbVie was mentioned in “final trades” and “below fair value”/discount-stock roundups, which may keep valuation-focused investors interested but are not company-specific operational news. Final trades: AbbVie, Morgan Stanley, Shake Shack and the CBOE
• Negative Sentiment: AbbVie received a Complete Response Letter from the FDA for TrenibotE, its fast-acting neurotoxin candidate. The agency cited manufacturing-related issues and raised no safety or efficacy concerns, but the delay still pushes back a potential new product launch. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE
• Negative Sentiment: AbbVie also terminated its deal with I-Mab to develop a cancer drug, removing a potential pipeline opportunity and signaling a setback in its oncology collaboration strategy. AbbVie terminates deal with I-Mab to develop cancer drug

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.